Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.
Abigail E SchiffXiaosong WangNaomi J PatelYumeko KawanoEmily N KowalskiClaire E CookKathleen M M VanniGrace QianKatarina J BadeAlene A SaavedraShruthi SrivatsanZachary K WilliamsRathnam K VenkatZachary S WallaceJeffrey A SparksPublished in: medRxiv : the preprint server for health sciences (2023)
Patients with RA who are using CD20 inhibitors or glucocorticoid monotherapy should be prioritized for risk mitigation strategies after the initial vaccine series of 3 mRNA doses.The impact of additional vaccine doses, timing of medication dosing, and other protective measures will need further study.